Literature DB >> 28798094

Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues.

David Montani1,2,3, Andrei Seferian4,2,3, Florence Parent4,2,3, Marc Humbert4,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28798094     DOI： 10.1183/13993003.01319-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  7 in total

1.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

Authors:  Mizuki Nishino; Lynette M Sholl; F Stephen Hodi; Hiroto Hatabu; Nikhil H Ramaiya
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

Review 2.  Immune-Related Adverse Events From Immune Checkpoint Inhibitors.

Authors:  K A Marrone; W Ying; J Naidoo
Journal:  Clin Pharmacol Ther       Date:  2016-07-29       Impact factor: 6.875

3.  Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.

Authors:  Anna J Lomax; Helen M McGuire; Catriona McNeil; Clara J Choi; Peter Hersey; Deme Karikios; Kerwin Shannon; Sebastian van Hal; Urszula Carr; Anne Crotty; Sandeep K Gupta; Jane Hollingsworth; Haewon Kim; Barbara Fazekas de St Groth; Neil McGill
Journal:  Int J Rheum Dis       Date:  2017-05-08       Impact factor: 2.454

4.  Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.

Authors:  Sree Harsha Tirumani; Nikhil H Ramaiya; Abhishek Keraliya; Nancy D Bailey; Patrick A Ott; F Stephen Hodi; Mizuki Nishino
Journal:  Cancer Immunol Res       Date:  2015-06-22       Impact factor: 11.151

Review 5.  Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

Authors:  S Champiat; O Lambotte; E Barreau; R Belkhir; A Berdelou; F Carbonnel; C Cauquil; P Chanson; M Collins; A Durrbach; S Ederhy; S Feuillet; H François; J Lazarovici; J Le Pavec; E De Martin; C Mateus; J-M Michot; D Samuel; J-C Soria; C Robert; A Eggermont; A Marabelle
Journal:  Ann Oncol       Date:  2015-12-28       Impact factor: 32.976

6.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Authors:  Myriam Delaunay; Jacques Cadranel; Amélie Lusque; Nicolas Meyer; Valérie Gounant; Denis Moro-Sibilot; Jean-Marie Michot; Judith Raimbourg; Nicolas Girard; Florian Guisier; David Planchard; Anne-Cécile Metivier; Pascale Tomasini; Eric Dansin; Maurice Pérol; Marion Campana; Oliver Gautschi; Martin Früh; Jean-David Fumet; Clarisse Audigier-Valette; Sébastien Couraud; Stéphane Dalle; Marie-Thérèse Leccia; Marion Jaffro; Samia Collot; Grégoire Prévot; Julie Milia; Julien Mazieres
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

Review 7.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

Authors:  Mizuki Nishino; Anita Giobbie-Hurder; Hiroto Hatabu; Nikhil H Ramaiya; F Stephen Hodi
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777
  7 in total
  1 in total

1.  Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer.

Authors:  Eliana La Rocca; Michela Dispinzieri; Laura Lozza; Gabriella Mariani; Serena Di Cosimo; Massimiliano Gennaro; Riccardo Valdagni; Maria Carmen De Santis
Journal:  Med Oncol       Date:  2018-11-15       Impact factor: 3.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.